Article Text

PDF
Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia

Statistics from Altmetric.com

Question:

What are the effects of ziprasidone compared with other atypical antipsychotics in people with schizophrenia and schizophrenia-like psychoses?

Outcomes:

Global state: no clinically important response (as defined by each study eg, <50% reduction on a rating scale, or global impression less than much improved); leaving study early (for any reason such as adverse events, inefficacy of treatment, weight gain etc.).

Methods

Design:

Systematic review with meta-analysis.

Data sources:

Cochrane Schizophrenia Group's Specialised Register was searched from inception to April 2007 for randomised controlled trials (RCTs). Reference lists of identified studies were hand searched. The first authors of the included studies were contacted for missing information, and drug companies were contacted for additional data.

Study selection and analysis:

Reviewers appraised studies and selected RCTs that compared oral ziprasidone with oral forms of risperidone, quetiapine, olanzapine, amisulpride, aripiprazole, clozapine, sertindole or zotepine in people with schizophrenia and schizophrenia-like psychoses. There were no restrictions on dose and language. Data were extracted independently. Weighted mean differences (MDs) were calculated for continuous …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles